In Every Issue
What’s New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Medical Simulation Corp (MSC) [...]
By
What’s New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Medical Simulation Corp (MSC) [...]
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Medical Simulation Corp (MSC) [...]
By
On The Cover
Controlling the Message in Cyber Space and Time
Keeping Up With the 2.0 Joneses To maintain a competitive edge in today’s crowded environment,most experts believe the industry needs to step up its 2.0 practices or get left behind in a swirl of networking dust. Not only may early adopters get a marketing leg up on companies that choose to drag their heels, but [...]
Keeping Up With the 2.0 Joneses To maintain a competitive edge in today’s crowded environment,most experts believe the industry needs to step up its 2.0 practices or get left behind in a swirl of networking dust. Not only may early adopters get a marketing leg up on companies that choose to drag their heels, but [...]
By
Robin Robinson
Features
HBA Leadership Conference
5th Annual HBA Leadership Conference 1 More than 500 industry leaders representing the Healthcare Businesswomen’s Association’s 10 chapters and three affiliates met in Washington,D.C., for an inspirational two?day conference, featuring a distinguished lineup of speakers and sessions. 2 4 7 1. Intrepid members of the HBA hit the streets on a chilly Washington,D.C.,morning to power [...]
5th Annual HBA Leadership Conference 1 More than 500 industry leaders representing the Healthcare Businesswomen’s Association’s 10 chapters and three affiliates met in Washington,D.C., for an inspirational two?day conference, featuring a distinguished lineup of speakers and sessions. 2 4 7 1. Intrepid members of the HBA hit the streets on a chilly Washington,D.C.,morning to power [...]
By
Developing a Formulary Formula
Managed MARKETS Experts on this Topic Sean Brandle. National Rx Practice Leader, The Segal Company, New York; The Segal Company is a private employee-owned actuarial and consulting firm. For more information, visit segalco.com. Larry Olson. VP and Practice Leader, Payer Markets, TNS Healthcare, New York; TNS Healthcare provides market research consulting and custom advisory services [...]
Managed MARKETS Experts on this Topic Sean Brandle. National Rx Practice Leader, The Segal Company, New York; The Segal Company is a private employee-owned actuarial and consulting firm. For more information, visit segalco.com. Larry Olson. VP and Practice Leader, Payer Markets, TNS Healthcare, New York; TNS Healthcare provides market research consulting and custom advisory services [...]
By
Managing Investigator Initiated Trials
Investigator initiated trials (IITs) can be a valuable part of a pharmaceutical or medical device manufacturer’s marketing claims arsenal, according to Rita Numerof, Ph.D., president, and Mark Morgan, M.S., senior business analyst, at Numerof & Associates Inc. The two contend that IITs are relatively low cost because much of the up front work is performed [...]
Investigator initiated trials (IITs) can be a valuable part of a pharmaceutical or medical device manufacturer’s marketing claims arsenal, according to Rita Numerof, Ph.D., president, and Mark Morgan, M.S., senior business analyst, at Numerof & Associates Inc. The two contend that IITs are relatively low cost because much of the up front work is performed [...]
By
Conquering the Divide — Joseph Pieroni
BY KIM RIBBINK Drawn initially to the lab as a medicinal chemist,then to the business side of pharma research, Joseph P. Pieroni has been able to straddle the often divided worlds of research and marketing seamlessly. This combination of skills and interests is great news for Daiichi Sankyo Inc., the U.S. subsidiary of Daiichi Sankyo [...]
BY KIM RIBBINK Drawn initially to the lab as a medicinal chemist,then to the business side of pharma research, Joseph P. Pieroni has been able to straddle the often divided worlds of research and marketing seamlessly. This combination of skills and interests is great news for Daiichi Sankyo Inc., the U.S. subsidiary of Daiichi Sankyo [...]
By
Kim Ribbink
Super Bugs
Bacteria have proven to be resourceful organisms. They are so resourceful that the widespread use of antibiotics in recent years has enabled bacteria to adapt and develop resistance to currently marketed treatments. Antibiotics stop infection and the spread of infection, yet they also eventually decrease in effective ness because of mutations of the pathogen. In [...]
Bacteria have proven to be resourceful organisms. They are so resourceful that the widespread use of antibiotics in recent years has enabled bacteria to adapt and develop resistance to currently marketed treatments. Antibiotics stop infection and the spread of infection, yet they also eventually decrease in effective ness because of mutations of the pathogen. In [...]
By
Cynthia Borda
MSLs: Evolution of Skills
The intent of the first MSL role, created in 1967 by the Upjohn Company, was to create a position within the pharmaceutical company that could interact with academiabased physicians and researchers. In the 1970s, the trend grew, with other companies mostly implementing MSL hir ing from within their own sales organizations. According to attorney Mark [...]
The intent of the first MSL role, created in 1967 by the Upjohn Company, was to create a position within the pharmaceutical company that could interact with academiabased physicians and researchers. In the 1970s, the trend grew, with other companies mostly implementing MSL hir ing from within their own sales organizations. According to attorney Mark [...]
By
Robin Robinson
Gene Therapy Research Makes Progress
With all the progress that has been made in genomics, targeting therapies to correct the defective genes responsible for disease seems quite realistic. But developing commercial gene therapies to treat diseases through modifying the expressions of an individual’s genes or correcting abnormal genes has proven to be more difficult. While hundreds of treatments that involve [...]
With all the progress that has been made in genomics, targeting therapies to correct the defective genes responsible for disease seems quite realistic. But developing commercial gene therapies to treat diseases through modifying the expressions of an individual’s genes or correcting abnormal genes has proven to be more difficult. While hundreds of treatments that involve [...]
By
Denise Myshko
